Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.45
-0.02 (-0.09%)
At close: Apr 16, 2026, 4:00 PM EDT
21.49
+0.04 (0.19%)
Pre-market: Apr 17, 2026, 4:05 AM EDT
DAWN Revenue
In the year 2025, Day One Biopharmaceuticals had annual revenue of $158.18M with 20.60% growth. Day One Biopharmaceuticals had revenue of $53.72M in the quarter ending December 31, 2025, with 83.92% growth.
Revenue (ttm)
$158.18M
Revenue Growth
+20.60%
P/S Ratio
14.01
Revenue / Employee
$888,663
Employees
178
Market Cap
2.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 158.18M | 27.02M | 20.60% |
| Dec 31, 2024 | 131.16M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Ultragenyx Pharmaceutical | 673.00M |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| Stoke Therapeutics | 184.42M |
| Syndax Pharmaceuticals | 172.35M |
| Mesoblast | 65.38M |
| Nektar Therapeutics | 55.23M |
DAWN News
- 5 weeks ago - Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 5 weeks ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
- 5 weeks ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
- 5 weeks ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
- 5 weeks ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
- 5 weeks ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
- 7 weeks ago - Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance - GlobeNewsWire
- 2 months ago - Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewsWire